Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.
Latest from Michael McCaughan
Some pharma industry CEOs appear to have done well in their meeting with President-elect Donald Trump and his health care team.
The US Medicare agency’s proposal to cover weight loss drugs hinges on defining obesity as a disease. While the characterization matches the growing medical consensus, the incoming Trump Administration may not agree.
The agency wants sponsors to design clinical trials more carefully where overall survival is not the primary endpoint.
The incoming Trump Administration’s “Department Of Government Efficiency” has big plans for sweeping cuts to the federal bureaucracy and regulation. The US FDA likely will feel some effects, but could avoid the most damaging mandates.
The incoming Trump Administration’s “Department Of Government Efficiency” has big plans for sweeping cuts to the federal bureaucracy and regulation. The US FDA likely will feel some effects, but could avoid the most damaging mandates.
The expected nominee for FDA commissioner has not been very kind to the agency in his public statements and President-elect Donald Trump appears to be urging him to shake things up.